The cardiologist's new video walks through why semaglutide lowered cardiovascular outcomes in people without diabetes, per SELECT trial results.
Recap by typeshit. Post by Dr Alo, DO, FACC on X.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
At least half a million Australians use the drugs each month, and experts warn the effects on teenagers are still poorly understood.
UK regulators and police entered an industrial unit on 14 October, with a warning for anyone who got their jab outside a pharmacy.
Loading…